Skip to content

Gideon P. Naudé

2 papers in the library · 8 citations · publishing 2026

Papers

Sort Most recent Most cited

Psilocybin or Nicotine Patch for Smoking Cessation

JAMA Network Open March 10, 2026 Mw Johnson, Gideon P. Naudé, Peter S. Hendricks et al. 6 citations

Importance: Annual tobacco-related death estimates are 480 000 in the US and 8 million worldwide, surpassing mortality for other abused substances. Most smoking cessation interventions result in modest long-term success. Objective: To compare prolonged smoking abstinence rates in smokers receiving psilocybin plus cognitive behavioral therapy (CBT) with those receiving the nicotine patch plus...

Pilot study of psilocybin in patients with post-treatment lyme disease

Scientific Reports February 25, 2026 Albert Garcia‐romeu, Gideon P. Naudé, Alison W. Rebman et al. 2 citations

Abstract Lyme disease, caused by the bacterium Borrelia burgdorferi , is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10–20% of patients develop post-treatment Lyme disease (PTLD), a chronic syndrome marked by fatigue, pain, cognitive difficulties, mood disturbance, and reduced quality of life. There are no...